Could Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) See a Reversal After More Sellers Came In?

September 17, 2017 - By Marguerite Chambers

 Could Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) See a Reversal After More Sellers Came In?

Investors sentiment increased to 0.94 in Q4 2016. Its up 0.64, from 0.3 in 2016Q3. It is positive, as 6 investors sold Catalyst Pharmaceuticals Inc shares while 12 reduced holdings. 9 funds opened positions while 8 raised stakes. 23.81 million shares or 1.65% more from 23.42 million shares in 2016Q3 were reported.
Manufacturers Life Insur The reported 3,218 shares. New York-based Broadfin Cap Limited has invested 0.96% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Commonwealth Equity Services owns 24,000 shares for 0% of their portfolio. Goldman Sachs Grp has invested 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Morgan Stanley holds 12,419 shares. Hbk Sorce Advisory Llc reported 21,109 shares. Raymond James Fincl Advisors Incorporated holds 0% or 15,500 shares. State Street Corp stated it has 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Kingdon Management Limited Com has invested 0.04% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Berson And Corrado Investment Advsr Llc invested in 190,600 shares. D E Shaw Co owns 12,651 shares or 0% of their US portfolio. Kennedy Mgmt Incorporated invested 0% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Geode Capital Ltd Com invested in 0% or 461,231 shares. Baker Bros Advsr Lp holds 5.10M shares or 0.05% of its portfolio. Susquehanna Intl Ltd Liability Partnership reported 59,541 shares or 0% of all its holdings.

The stock of Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) registered an increase of 1.17% in short interest. CPRX’s total short interest was 6.53 million shares in September as published by FINRA. Its up 1.17% from 6.46M shares, reported previously. With 455,900 shares average volume, it will take short sellers 14 days to cover their CPRX’s short positions. The short interest to Catalyst Pharmaceuticals Incorporated’s float is 11.5%.

The stock decreased 6.23% or $0.16 on September 15, reaching $2.41. About 1.10 million shares traded or 74.67% up from the average. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has risen 267.48% since September 17, 2016 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has market cap of $203.78 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Ratings Coverage

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 8 analyst reports since April 26, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 11 by H.C. Wainwright. As per Thursday, August 10, the company rating was maintained by Roth Capital. The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has “Buy” rating given on Friday, September 1 by SunTrust. The firm earned “Overweight” rating on Wednesday, October 5 by Piper Jaffray. The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has “Overweight” rating given on Wednesday, October 5 by PiperJaffray. The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has “Buy” rating given on Monday, August 7 by Piper Jaffray. The rating was downgraded by Piper Jaffray on Tuesday, April 26 to “Neutral”. On Wednesday, August 30 the stock rating was maintained by Roth Capital with “Buy”.

More notable recent Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) news were published by: Nasdaq.com which released: “Why is Catalyst Pharmaceuticals’ Stock Up 160% this Year?” on June 28, 2017, also Nasdaq.com with their article: “Why Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?” published on June 14, 2017, Zacks.com published: “Catalyst Pharmaceuticals Focuses on Development of Firdapse” on May 23, 2017. More interesting news about Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) were released by: Globenewswire.com and their article: “Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference” published on June 01, 2017 as well as Globenewswire.com‘s news article titled: “Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and …” with publication date: August 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.